Literature DB >> 11739423

The complete normalization of the adrenocortical function as the criterion of cure after transsphenoidal surgery for Cushing's disease.

J Estrada1, J García-Uría, C Lamas, J Alfaro, T Lucas, S Diez, L Salto, B Barceló.   

Abstract

Transsphenoidal microsurgery is the standard treatment for patients with Cushing's disease. However, there is general lack of agreement regarding the definition of cure. We studied 58 patients with corrected hypercortisolism after transsphenoidal surgery for Cushing's disease. Plasma and urinary cortisol levels were measured after surgery. After the postsurgical hypocortisolism stage (or periodically in patients without hypocortisolism), urinary free cortisol, plasma cortisol at 0800 h and 2300 h, morning cortisol after 1 mg dexamethasone, and cortisol response to insulin-induced hypoglycemia were performed. Patients were classified in 3 groups: group I, patients with transient hypocortisolism and normal hypothalamus-pituitary-adrenal axis afterwards; group II, patients with transient hypocortisolism and abnormalities in the circadian rhythm or the stress response afterwards; and group III, patients without postoperative hypocortisolism. Thirty-three patients were included in group I, 8 in group II, and 17 in group III. Groups I and II were similar in postsurgical plasma cortisol (46.9 +/- 30.3 vs. 60.7 +/- 38.6 nM) and mean follow-up (69.8 vs. 68.8 months) but were significantly different in their recurrence rate (3.4% vs. 50%, P < 0.001). Patients in group III had normal postsurgical plasma and urinary cortisol but persistent abnormalities in circadian rhythm and stress response. After a mean follow-up of 39.1 months, their recurrence rate was similar to that of group II (64.7% vs. 50%). The complete normalization of the adrenocortical function, which is always preceded by postsurgical hypocortisolism, is associated with a very low recurrence risk and should be considered, in our opinion, the main criterion of surgical cure in Cushing's disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11739423     DOI: 10.1210/jcem.86.12.8069

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  22 in total

Review 1.  Characterization of persistent and recurrent Cushing's disease.

Authors:  Nina K Sundaram; Alessia Carluccio; Eliza B Geer
Journal:  Pituitary       Date:  2014-08       Impact factor: 4.107

2.  Determinants of neurosurgical outcome in pituitary tumors.

Authors:  M J Barahona; L Sojo; A M Wägner; F Bartumeus; B Oliver; P Cano; S M Webb
Journal:  J Endocrinol Invest       Date:  2005-10       Impact factor: 4.256

3.  Clinical manifestations and hormonal profile of two women with Cushing's disease and mild deficiency of 21-hydroxylase.

Authors:  M Boronat; A Carrillo; A Ojeda; J Estrada; B Ezquieta; F Marín; F J Nóvoa
Journal:  J Endocrinol Invest       Date:  2004-06       Impact factor: 4.256

Review 4.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

Review 5.  The role of somatostatin analogs in Cushing's disease.

Authors:  Joost van der Hoek; Steven W J Lamberts; Leo J Hofland
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

Review 6.  Approach to the postoperative patient with Cushing's disease.

Authors:  Martin J Rutkowski; Jonathan D Breshears; Sandeep Kunwar; Manish K Aghi; Lewis S Blevins
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

7.  Delayed remission after transsphenoidal surgery in patients with Cushing's disease.

Authors:  Elena Valassi; Beverly M K Biller; Brooke Swearingen; Francesca Pecori Giraldi; Marco Losa; Pietro Mortini; Douglas Hayden; Francesco Cavagnini; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2010-01-15       Impact factor: 5.958

8.  Remission rate after transsphenoidal surgery in patients with pathologically confirmed Cushing's disease, the role of cortisol, ACTH assessment and immediate reoperation: a large single center experience.

Authors:  Nadia Hameed; Chris G Yedinak; Jessica Brzana; Sakir H Gultekin; Nicholas D Coppa; Aclan Dogan; Johnny B Delashaw; Maria Fleseriu
Journal:  Pituitary       Date:  2013-12       Impact factor: 4.107

Review 9.  Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.

Authors:  B M K Biller; A B Grossman; P M Stewart; S Melmed; X Bertagna; J Bertherat; M Buchfelder; A Colao; A R Hermus; L J Hofland; A Klibanski; A Lacroix; J R Lindsay; J Newell-Price; L K Nieman; S Petersenn; N Sonino; G K Stalla; B Swearingen; M L Vance; J A H Wass; M Boscaro
Journal:  J Clin Endocrinol Metab       Date:  2008-04-15       Impact factor: 5.958

Review 10.  An approach to the management of patients with residual Cushing's disease.

Authors:  Lewis S Blevins; Nader Sanai; Sandeep Kunwar; Jessica K Devin
Journal:  J Neurooncol       Date:  2009-04-19       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.